Skip to content
MARKETS / NASDAQ / NTLA
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE CAP

Intellia Therapeutics, Inc. NTLA

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$67.7M
▲ 16.9% YoY
$-412.7M
$-395.9M
In brief

What this company does

For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles, to develop novel, first-in-class product candidates. As of February 13, 2026, Intellia had 377 full-time employees, 263 of whom were primarily engaged in research and development activities and 106 of whom have an M.D. or Ph.D. degree. Intellia was incorporated under the laws of the State of Delaware in May 2014 under the name AZRN, Inc. and amended its certificate of incorporation in July 2014 to change its name to Intellia Therapeutics, Inc.

Written from the business description in INTELLIA THERAPEUTICS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 67.7M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 67.7 · Net income -412.7
25.0M50.0M-200.0M-400.0M201520172019202120232025
Compound annual growth
+9.1%
+3.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−610 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -651.7% · Net -609.9%
-500%-1000%201520172019202120232025
ROE
FY2025 · ROE -53.5%
-50%-100%-150%201520172019202120232025

Each USD of equity lost 53 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -395.9
-200M-400M201520172019202120232025

Total assetsUSD 842.1M
EquityUSD 671.4M
CashUSD 155.5M
Current ratio5.08×

Equity funds 80% of total assets.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B0.10.10.00.10.00.10.00.00.00.0·
Operating income $B−0.4−0.5−0.5−0.5−0.3−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.4−0.5−0.5−0.5−0.3−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.0········0.0−0.0
Net income $B−0.4−0.5−0.5−0.5−0.3−0.1−0.5−0.1−0.1−0.0−0.0
Free cash flow $B−0.4−0.4−0.4−0.3−0.2−0.1−0.1−0.1−0.10.0−0.0
EPS, diluted $−3.81−5.25−5.42−6.16−3.78−2.40−2.11−1.98−1.88−1.42−51.02
Dividend / sh $···········
Payout %···········
ROE %−53.5−54.0−42.1−41.7−34.2−33.7−173.1−29.5−26.5−33.5·
Shares out B0.120.100.090.090.070.070.050.050.040.040.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 44 reconciliationsAUDITED

Reconciled in 11 of 19 fiscal years. 47 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image